Technical Analysis

52-WEEK FLOP: PANACEA BIOTECH

Srividhya Sivakumar | Updated on March 09, 2018 Published on March 10, 2012

11panaceaCol.eps0

PanaceaTabCol.eps1

Panacea Biotech, one of the largest vaccine producer in the country, has had a distressed one year. While the goings were smooth in the first half of the year, it was in the second half that its troubles began.

In July 2011, following a routine site audit by a World Health Organisation (WHO) team, its DTP-based combination and monovalent hepatitis B vaccines were delisted from WHO's list of pre-qualified vaccines. Sure enough, the company went into the red next quarter onwards.

In the September and December 2011 quarter, it reported losses of about Rs 34 crore and Rs 72 crore respectively. In the December quarter, its sales of vaccines declined to Rs 69 crore from Rs 212 crore in the corresponding quarter last year. This was driven mainly by the delisting of the pentavalent vaccine, which may help put the severity of the development in perspective.

The company has reported losses of about Rs 89 crore (profit of Rs 92 crore last year) even in the nine-month period. While it has since taken several corrective and preventive measures, its panacea will lie in getting a re-listing of its pentavalent vaccine in the list of WHO pre-qualified vaccines soon.

That in January this year the Income Tax Department conducted searches at its premises for alleged evasion of taxes worth crores did not help its cause either.

Published on March 10, 2012

A letter from the Editor


Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Support Quality Journalism
This article is closed for comments.
Please Email the Editor
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.